10x Genomics (TXG) Misses Q4 EPS by 6c, provides guidance

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.41), $0.06 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $184 million versus the consensus estimate of $182.4 million.

GUIDANCE:

10x Genomics sees Q1 2024 revenue of $670-690 million, versus the consensus of $702.3 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Goldman Sachs Upgrades SK Innovation Co Ltd (096770:KS) to Neutral
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)